Robert E. Gagnon - Sep 2, 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Role
Chief Financial Officer
Signature
/s/ Amy Rabourn, by Power of Attorney
Stock symbol
IRD
Transactions as of
Sep 2, 2025
Transactions value $
$0
Form type
4
Date filed
9/11/2025, 06:03 PM
Previous filing
Jul 18, 2025
Next filing
Sep 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gagnon Robert E. Chief Financial Officer C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM /s/ Amy Rabourn, by Power of Attorney 2025-09-11 0001504983

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRD Common Stock Award $0 +200K $0.00 200K Sep 10, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRD Employee Stock Option (right to buy) Award $0 +250K $0.00 250K Sep 2, 2025 Common Stock 250K $1.23 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.
F2 The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.